

## Formulary Exception/Prior Authorization Request Form

Patient Information Patient Name:		Prescriber Information Prescriber Name:			
T dilottitation					
Patient ID#: Address:		Address:			
Addless		Addiess.			
City:	State:	City:			State:
Home Phone:	ZIP:	Office Pho	ne #:	Office Fax #:	ZIP:
Gender: M or F	DOB:	Contact Person at Doctor's Office:			
Diagnosis and Medical Information					,
Medication:	Strength:	Directions for use (Frequency):		uency):	
Expected Length of Therapy:	Qty:	Day Supply:		ontinuation of therapy, how long has been on the medication?	
Diagnosis:		Diagnosis (ICD) Code(s):			
FORM CANNOT BE EVALUATION FORM CANNOT BE EVALUATION FOR TAXABLE TO THE PROPERTY OF THE PROPERTY OF TAXABLE TO T	cking this bo the patient o	x and signi r the patien	ng below, I t's ability to	certify that applying to regain maximum fun	he standard review time oction.
Please list all medications the patient has tried specific to the dia Medication name, reason for failure, including trial yea					
Drug(s) contraindicated:					
Adverse event (e.g., toxicity, allergy) for each drug:					
Is the request for a patient with one or more chronic conditions (eat high risk for a significant adverse event with a medication cha					rrent drug(s) and who might b
Does the patient have a chronic condition confirmed by diagnost	tic testing? If so,	, please provid	de diagnostic t	est and date:	
Does the patient have a clinical condition for which other formula clinical literature? If so, please provide documentation:	ary alternatives	are not recom	mended or ar	e contraindicated based or	n published guidelines or
Does the patient require a specific dosage form (e.g., suspensio	n, solution, inje	ction)? If so, pl	ease provide	dosage form:	
Does the patient have any risk factors present or are there any c provide documentation:		sthat should b	e considered	(e.g., comorbidities, drug i	nteractions)? If so, please
Does the patient have an insulin pump? If so, please provide ma	ake and model (	e .g., Accu-Ch	ekCombo, Or	mniPod, MiniMed 530G): _	
REQUIRED CLINICAL INFORMATION: PLEASE PROVIDE ALL RELEVANT CLINICAL DOCUMENTATION TO SUPPORT USE OF THIS MEDICATION.					
PLEASE COMPLETE CORRESPONDING SECTION ON PAGE 2 FOR THE SPECIFIC DRUGS/CLASSES LISTED.					
**FOR ANY DRUG/CLASS NOT LISTED ON PAGE 2, PLEASE ATTACH ADDITIONAL INFORMATION, BUT CANNOT EXCEED TWO PAGES.**					
PRESCRIPTION BENEFIT PLAN MAY REQUEST ADD	ITIONAL INFO	RMATION OR	CLARIFICAT	ΠΟΝ, IF NEEDED, TO EV	ALUATE REQUESTS.
PLEASE F	AX COMPLETE	ED FORM TO	1-888-836-07	730.	
I attest that the medication requested is medically necessary for this part information is available for review if requested by CVS Caremark, the hundred knowingly makes or causes to be made a false record or statement that to civil penalties and treble damages under both the federal and state F	ealth plan sponso t is material to a cl	r, or, if applicable aim ultimately pa	e, a state or fed aid by the Unite	eral regulatory agency. I under d States government or any st	rstand that any person who
Prescriber Signature: Date:					

Confidentiality Notice: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return fax) and arrange for the return or destruction of these documents.

	ASE COMPLETE CORRESPONDING SECTION FOR THESE SPECIFIC DRUGS/CLASSES LISTED BELOW AND CIRCLE THE APPROPRIATE WER OR SUPPLY RESPONSE.  ANTIFUNGALS:
1. 2.	Does the patient have a diagnosis of onychomycosis due to tinea unguium? <b>Yes or No</b> If yes to question 1, is the onychomycosis confirmed by a fungal diagnostic test? <b>Yes or No</b> Does the infection involve the toenails, fingemails or both? ( <b>Please circle</b> )
<ul><li>3.</li><li>4.</li></ul>	Is the request for treatment of tinea corporis or tinea cruris in a patient who is immunocompromised or has extensive or complicated infection? <b>Yes or No</b> If yes to question 3, does the patient require systemic therapy or have more extensive superficial infections? <b>Yes or No</b> Has the patient experienced an inadequate treatment response, intolerance or contraindication to an oral antifungal therapy? <b>Yes or No</b>
1. 2.	ANTIEMETIC (5-HT3) AGENTS: Is the patient receiving moderate to highly emetogenic chemotherapy or receiving radiation therapy? Yes or No Is the patient pregnant with the diagnosis of Hyperemesis Gravidarum and a documented risk for hospitalization? Yes or No If yes to question 2, has the patient experienced an inadequate treatment response, intolerance or contraindication to two of the following medications: Vitamin B6, doxylamine, doxylamine/pyridoxine extended-release (Boniesta), doxylamine/pyridoxine delayed-release (Diclegis), promethazine (Phenergan), trimethobenzamide (Tigan) or metoclopramide (Reglan)? Yes or No
1.	ERECTILE DYSFUNCTION:  Does the patient require nitrate therapy on a regular OR on an intermittent basis or will the patient be taking a guanylate cyclase (GC) stimulator, such as riociguat? Yes or No
2. 3.	Is the drug being prescribed for erectile dysfunction? <b>Yes or No</b> Is the drug being prescribed for symptomatic Benign Prostatic Hyperplasia (BPH)? <b>Yes or No</b>
1. 2.	INSOMNIA AGENTS:  Does the patient have a diagnosis of insomnia? Yes or No  Have potential causes of sleep disturbances been addressed (e.g., inappropriate sleep hygiene and sleep environment issues, treatable medical/psychological causes of chronic insomnia)? Yes or No
1. 2. 3.	PROTON PUMP INHIBITORS:  Does the patient have peptic ulcer disease OR frequent and severe symptoms of gastroesophageal reflux disease (GERD) (e.g., heartburn, regurgitation) OR atypical symptoms or complications of GERD (e.g., dysphagia, hoarseness, erosive esophagitis)? Yes or No  Does the patient have Barrett'sesophagus as confirmed by biopsy OR a Hypersecretory syndrome (e.g. Zollinger-Ellison) confirmed with a diagnostic test? Yes or No  Is the patient at high risk for GI adverse events? Yes or No
1. 2. 3. 4.	PROVIGIL/NUVIGIL:  Does the patient have a diagnosis of Shift Work Disorder (SWD)? Yes or No  Does the patient have a diagnosis of Obstructive Sleep Apnea confirmed by polysomnography? Yes or No  Does the patient have a diagnosis of Narcolepsy confirmed by sleep lab evaluation? Yes or No  Is the request for Provigil, and does the patient have a diagnosis of fatigue related to multiple sclerosis? Yes or No  If yes to question 4, has the patient had an inadequate treatment response, intolerance or contraindication to amantadine? Yes or No
1. 2. 3. 4.	STIMULANTS: AMPHETAMINES, METHYLPHENIDATES, STRATTERA  Does the patient have a diagnosis of attention deficit/hyperactivity disorder (ADHD) or attention deficit disorder (ADD)? Yes or No Has the diagnosis been documented (i.e., complete clinical assessment, using DSM-5®, standardized rating scales)? Yes or No Does the patient have a diagnosis of Narcolepsy confirmed by sleep lab evaluation? Yes or No Does the patient have a diagnosis of moderate to severe binge eating disorder (BED)? Yes or No
□ 1.	TRETINOIN PRODUCTS:  Does the patient have the diagnosis of acne vulgaris or keratosis follicularis? Yes or No
1. 2. 3. 4.	TAZORAC:  Does the patient have a diagnosis of acne vulgaris? Yes or No  Does the patient have a diagnosis of plaque psoriasis? Yes or No  Will the patient be applying Tazorac to less than 20 percent of body surface area? Yes or No  Has the patient had intolerance, inadequate treatment response or contraindication to one topical corticosteroid? Yes or No
1. 2. 3.	TESTOSTERONE PRODUCTS:  Does the patient have primary or secondary (hypogonadotropic) hypogonadism? Yes or No  Does the patient have age-related hypogonadism? Yes or No  Does the patient have at least two confirmed low testosterone levels according to current practice guidelines or your standard male lab reference values?  Yes or No  Is the drug being prescribed for female-to-male gender reassignment? Yes or No
1. 2. 3. 4. 5.	TRIPTANS:  Does the patient have confirmed or suspected cardiovascular or cerebrovascular disease, or uncontrolled hypertension? Yes or No Does the patient have a diagnosis of migraine headache or cluster headache? Please circle one Is the patient currently using or unable to use migraine prophylactic therapy (e.g., amitriptyline, propranolol, timolol)? Yes or No Has medication overuse headache been considered and ruled out? Yes or No Does the patient need an amount for treating more than eight headachesper month with a 5-HT1 agonist? Yes or No

**VOLTAREN GEL:** 

Does the patient have osteoarthritis pain in joints susceptible to topical treatment such as feet, ankles, knees, hands, wrist or elbow? Yes or No Is the treatment with the requested drug necessary due to intolerance or a contraindication to oral nonsteroidal anti-inflammatory (NSAID) drugs?

Does the patient require more than 32 grams (16 two gram doses or 8 four gram doses) per day over all affected joints? Yes or No